Boston Oncology Arabia develops and manufactures internationally licensed bio-generic and biosimilar therapeutics, supplying vital medicines for oncology and critical care. The company focuses on locally producing specialty generics and biosimilars using already approved formulations to meet pharmaceutical quality, safety, and efficacy standards. Its headquarters are in Riyadh and manufacturing is at a production facility in Sudair Industrial City. Boston Oncology Arabia’s localization model and international licensing relationships from Western and Eastern markets support expanded access to life-saving specialty drugs across the GCC and MENA region. The company positions itself to become a key Saudi provider of specialty generics and biosimilars and contributes to Saudi Vision 2030 by increasing local production and reducing healthcare costs. TVM Capital Healthcare’s involvement is expected to expedite the company’s move into full formulation and fill-and-finish manufacturing and to broaden its access to international suppliers and licensing partners.

Total raised

$35M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024